These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34864807)

  • 1. In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and MDS.
    Freudenreich M; Tischer J; Kroell T; Kremser A; Dreyßig J; Beibl C; Liepert A; Kolb HJ; Schmid C; Schmetzer H
    J Immunother; 2022 Feb-Mar 01; 45(2):104-118. PubMed ID: 34864807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC
    Ansprenger C; Amberger DC; Schmetzer HM
    Clin Immunol; 2020 Aug; 217():108467. PubMed ID: 32464186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture.
    Unterfrauner M; Rejeski HA; Hartz A; Bohlscheid S; Baudrexler T; Feng X; Rackl E; Li L; Rank A; Filippini Velázquez G; Schmid C; Schmohl J; Bojko P; Schmetzer H
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
    J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays.
    Schutti O; Klauer L; Baudrexler T; Burkert F; Schmohl J; Hentrich M; Bojko P; Kraemer D; Rank A; Schmid C; Schmetzer H
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.
    Amberger DC; Schmetzer HM
    Transfus Med Hemother; 2020 Dec; 47(6):432-443. PubMed ID: 33442338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Das TP; North D; Fleming SA; Tan JLC; Ivey A; Cummings NJ; Spencer A; Patil SS; Widjaja JML; Swain MI; Bourke C; O'Brien ME; Kliman DS; Curtis DJ
    Transplant Cell Ther; 2023 Jul; 29(7):454.e1-454.e8. PubMed ID: 36966870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Leukemic Effects Induced by Dendritic Cells of Leukemic Origin from Leukemic Blood Samples Are Comparable under Hypoxic vs. Normoxic Conditions.
    Doraneh-Gard F; Amberger DC; Amend C; Weinmann M; Schwepcke C; Klauer L; Schutti O; Hosseini H; Krämer D; Rank A; Schmid C; Schmetzer HM
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions.
    Merle M; Fischbacher D; Liepert A; Grabrucker C; Kroell T; Kremser A; Dreyssig J; Freudenreich M; Schuster F; Borkhardt A; Kraemer D; Koehne CH; Kolb HJ; Schmid C; Schmetzer HM
    Immunobiology; 2021 May; 226(3):152088. PubMed ID: 33838552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Dreyssig J; Kremser A; Liepert A; Grabrucker C; Freudenreich M; Schmid C; Kroell T; Scholl N; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer HM
    Immunotherapy; 2011 Sep; 3(9):1113-24. PubMed ID: 21913833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
    Yanada M; Mizuno S; Yamasaki S; Harada K; Konuma T; Tamaki H; Shingai N; Uchida N; Ozawa Y; Tanaka M; Onizuka M; Sawa M; Nakamae H; Shiratori S; Matsuoka KI; Eto T; Kawakita T; Maruyama Y; Ichinohe T; Kanda Y; Atsuta Y; Aoki J; Yano S
    Leuk Lymphoma; 2021 Dec; 62(14):3411-3419. PubMed ID: 34348554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience.
    Bagheri K; Alimoghadam K; Pourfathollah AA; Hassan ZM; Hajati J; Moazzeni SM
    Pathol Oncol Res; 2009 Jun; 15(2):257-67. PubMed ID: 18807213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
    Koh H; Nakamae H; Hagihara K; Nakane T; Manabe M; Hayashi Y; Nishimoto M; Umemoto Y; Nakamae M; Hirose A; Inoue E; Inoue A; Yoshida M; Bingo M; Okamura H; Aimoto R; Aimoto M; Terada Y; Koh KR; Yamane T; Ohsawa M; Hino M
    J Exp Clin Cancer Res; 2011 Apr; 30(1):36. PubMed ID: 21477348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
    Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
    Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.